Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site

Mumbai: Supriya Lifescience Ltd has inaugurated its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. The facility, developed with an investment of approximately Rs 125 crore, adds a substantial capacity of 335 kiloliters to the company’s operations.

This expansion boosts the company's Lote Parshuram capacity by over 55%, increasing it from 597 KLPD to 932 KLPD.

The new production block is designed to support Supriya Lifescience’s strategic focus on expanding its R&D capabilities. Several new products in niche therapeutic areas are nearing the commercialization stage, as per the release.

Spread across 5,000 square meters and structured over four levels, the facility will support the company’s backward integration model, ensuring economies of scale and a competitive edge. The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL. Incorporating closed-system handling at critical stages, the facility is equipped with process control automation systems and material handling systems.

Dr. Satish Wagh, Executive Chairman & WTD, Supriya Lifescience Ltd, commenting on the occasion, said, “We are excited to inaugurate our new manufacturing Module E block. With the latest technologies and our team’s dedication, we are poised to elevate product quality, ensure efficiency through backward integration, and meet growing global demand. Module E is a testament to our strategic focus on innovation and sustainability, serving as a key driver of growth while reducing dependence on imports. As Supriya Lifescience continues to strengthen its infrastructure and expand its product porƞolio, the company remains dedicated to seƫng new benchmarks in the pharmaceutical industry and delivering value to its stakeholders."